Hansoh Pharmaceutical Receives Clinical Trial Approval for NASH Drug HS-10356

On May 27, Hansoh Pharma announced that its Class 1 innovative drug "HS-10356 Tablets," independently developed by its subsidiaries Jiangsu Hansoh Pharmaceutical Group Co., Ltd. and Shanghai Hansoh BioMedical Co., Ltd., received the Notice of Approval for Clinical Trials issued by the National Medical Products Administration of the People's Republic of China on May 26, 2020. The drug is intended for the treatment of non-alcoholic steatohepatitis (NASH), with the specific indications to be determined following clinical trials.